During the past decade, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 14 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 10 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Pfizer" with 5 trials sponsored, "Celgene" with 4 trials sponsored, "Daiichi Sankyo, Inc." with 3 trials sponsored and "Janssen Research & Development, LLC" with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital" #1 collaborator was "Japan Agency for Medical Research and Development" with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Epidemiological and Clinical Research Information Network" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital" are "Non-Small Cell Lung Cancer" (4 trials), "Breast Cancer" (3 trials), "Chronic Myeloid Leukemia" (3 trials), "Acute Myeloid Leukemia" (2 trials) and "Gastrointestinal Stromal Tumor" (2 trials). Many other conditions were trialed in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital" are "Drug" (40 trials), "Other" (4 trials), "Biological" (2 trials), "Genetic" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pemetrexed" (6 trials), "Carboplatin" (5 trials), "Cisplatin" (4 trials), "Placebo" (4 trials) and "Atezolizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital" are 38 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital". undefined are not yet recruiting, 10 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 24 completed trials in Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 5 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".